Shares of Pfizer Inc. PFE are making a large move higher Tuesday. But the stock has run into resistance.It may be about to break out. This could be followed by a new uptrend. This is why our team of traders and technical analysts has made it our Stock of the Day.Some analysts are attributing the move to the company's reaffirmation of its guidance. Pfizer sees annual sales between $61 billion and $64 billion. It also sees earnings of between $2.75 and $2.95 per share. Both numbers are in line with estimates. ...

Pfizer Inc. (NYSE:PFE) Full-Year 2025 Financial Guidance Conference Call December 17, 2024 8:30 AM ET Company Participants Francesca DeMartino - Chief IRO and SVP Albert Bourla - Chairman and CEO David Denton - CFO Conference Call Participants Chris Schott - JPMorgan Geoff Meacham - Citibank Steve Scala - TD Securities Tim Anderson - Bank of America Chris Shibutani - Goldman Sachs Trung Huynh - UBS Vamil Divan - Guggenheim Evan Seigerman - BMO Capital Markets Operator Good day, everyone, and welcome to Pfiz ...

Key TakeawaysPfizer on Tuesday affirmed its full-year 2024 projections and issued 2025 revenue and adjusted profit guidance in line with analysts' estimates.The drugmaker expects revenue from $61 billion to $64 billion for both 2024 and 2025, and expects adjusted earnings per share to grow in 2025.Pfizer has returned to year-over-year revenue growth in its two most recent quarters for the first time since COVID vaccine sales peaked. Pfizer (PFE) shares rose Tuesday morning after the pharmaceutical company a ...

Pharma stocks Pfizer Inc (NYSE:PFE) and Teva Pharmaceutical Industries Ltd (NYSE:TEVA) are in the spotlight today. The former's 2025 profit outlook came in above expectations, and the latter's drug with Sanofi (SNY) met the main goal of a mid-stage trial of being an effective treatment for Crohn's disease and ulcerative colitis. PFE was last seen up 3.7% at $26.18, chipping away at its 12.9% year-to-date deficit. A floor at $25 contained the equity's most recent pullback, while above the 40-day moving avera ...

About this content About Josh Lamb After graduating from the University of Kent in the summer of 2022 with a degree in History, Josh joined Proactive later that year as a journalist in the UK editorial team. Josh has reported on a range of areas whilst at Proactive, including energy companies during a time of global crisis, aviation and airlines as the sector recovers from the pandemic, as well as covering economic, social and governance issues. Read more About the publisher Proactive financial news and ...

On Tuesday, Pfizer Inc. PFE released its full-year 2025 financial guidance, projecting revenues between $61.0 billion and $64.0 billion compared to a consensus of $63.28 billion.For 2025, Pfizer expects revenue from COVID-19 products to remain consistent with 2024, excluding approximately $1.2 billion in one-time Paxlovid revenue recognized in 2024.The guidance accounts for an estimated $1 billion net unfavorable revenue impact due to changes under the Inflation Reduction Act (IRA), particularly Medicare Pa ...

Pfizer Inc. PFE will conduct an investor call on Tuesday to provide full-year 2025 financial guidance.Ahead of the call, Goldman Sachs has outlined its expectations for the guide and commentary on the upcoming year.The analyst anticipates that Pfizer’s management will guide to EPS in the mid-to-high $2 range with core business growth offset by the $0.30 in favorable but non-recurring items during 2024.Pfizer highlighted several factors affecting its 2024 EPS that won’t carry over to 2025.The 2024 EPS includ ...

I am focused on growth and dividend income. My personal strategy revolves around setting myself up for an easy retirement by creating a portfolio which focuses on compounding dividend income and growth. Dividends are an intricate part of my strategy as I have structured my portfolio to have monthly dividend income which grows through dividend reinvestment and yearly increases. Feel free to reach out to me on Seeking AlphaAnalyst’s Disclosure: I/we have a beneficial long position in the shares of PFE, ABBV e ...

Pharmaceutical and biotech stocks often are seen as steady and safe options for investors for one particular reason. Patients need their medications, so regardless of the economic environment, these companies generally see at least stability in revenue. But it's important to note that you can turn to these players for growth too.Drugmakers often see phases of growth as they develop candidates for a high-potential treatment area or as they launch promising new products. Over time, you can benefit from these ...

With a market capitalization of more than $143 billion today, Pfizer (PFE 0.83%) stock won't make anyone into a millionaire unless they're willing to commit a large amount of capital and then hold the stock for a very long period of time, reinvesting all the dividends they receive along the way. Big pharma businesses simply don't grow quickly enough to deliver investors the massive returns that are necessary to generate millions from a humble starting sum.There's no evidence that Pfizer is about to change i ...